Reduced intestinal‐to‐diffuse conversion and immunosuppressive responses underlie superiority of neoadjuvant immunochemotherapy in gastric adenocarcinoma
Neoadjuvant immunochemotherapy (NAIC) achieves superior clinical benefits over neoadjuvant chemotherapy (NAC) in multiple types of human cancers, including gastric adenocarcinoma (GAC). However, it is poorly understood how the malignant epithelial cells and tumor immune microenvironment (TIME) might respond distinctly to NAIC and NAC that underlies therapeutic efficacy. Here treatment-naive and paired tumor tissues from multiple centers were subjected to pathological, immunological, and transcriptomic analysis. NAIC demonstrated significantly increased rate of pathological complete response compared to NAC (pCR: 25% vs. 4%, <i>p </i>< 0.05). Interestingly, pretreatment intestinal subtype of Lauren's classification was predictive of pathologic regression following NAIC, but not NAC. A substantial portion of cancers underwent intestinal-to-diffuse transition, which occurred less following NAIC and correlated with treatment failure. Moreover, NAIC prevented reprogramming to an immunosuppressive TIME with less active fibroblasts and exhausted CD8<sup>+</sup> T cells, and increased numbers of mature tertiary lymphoid structures. Mechanistically, activation of the tumor necrosis factor alpha (TNFα)/nuclear factor-kappa B (NF-κB) signaling pathway was associated with response to NAIC. Together, NAIC is superior to NAC for locally advanced GAC, likely due to reduced intestinal-to-diffuse conversion and reprogramming to an immuno-active TIME. Modulation of the histological conversion and immunosuppressive TIME could be translatable approaches to improve neoadjuvant therapeutic efficacy.
Authors
- Wenkang Liu (ORCID: https://orcid.org/0000-0002-4880-0897)
- Linghong Wan (ORCID: https://orcid.org/0009-0002-4282-0421)
- Yongying Hou
- Zhenning Wang (ORCID: https://orcid.org/0000-0003-0557-3097)
- Yutang Ren (ORCID: https://orcid.org/0000-0002-8972-5846)
- Shunan Wang (ORCID: https://orcid.org/0000-0001-8658-6441)
- Shuoran Tian
- Mengxia Li (ORCID: https://orcid.org/0000-0003-4443-740X)
- Mengsi Zhang (ORCID: https://orcid.org/0009-0008-5377-8939)
- Linyu Wu (ORCID: https://orcid.org/0000-0001-7695-0385)
- Zhong‐yi Qin (ORCID: https://orcid.org/0000-0002-5504-9480)
- Bin Wang (ORCID: https://orcid.org/0000-0002-3576-4807)
- Jinyang Li (ORCID: https://orcid.org/0000-0001-8125-6603)
- Fan Li (ORCID: https://orcid.org/0000-0001-6183-1893)
- Qin Liu (ORCID: https://orcid.org/0000-0003-1951-854X)
- Tao Wang (ORCID: https://orcid.org/0000-0002-9623-8800)
- Xianfeng Li (ORCID: https://orcid.org/0000-0002-9394-9682)
- Dongfeng Chen
- Xu Chen (ORCID: https://orcid.org/0009-0004-4759-0893)
- Mengyi Han (ORCID: https://orcid.org/0009-0008-8642-6809)
- Peng Gao (ORCID: https://orcid.org/0000-0003-3807-2563)
- Yuwei Pan (ORCID: https://orcid.org/0000-0003-0971-722X)
- Shiyin Peng (ORCID: https://orcid.org/0000-0002-6484-0805)
- Yuting Tan
- Haihui Wen
- Junyu Xiang
- Chuan Chen (ORCID: https://orcid.org/0000-0001-7491-9165)
- Lei Wang (ORCID: https://orcid.org/0000-0003-0734-7026)
Institutions
- Army Medical University (CN)
- Chongqing University (CN)
- Daping Hospital (CN)
- People's Liberation Army 401 Hospital (CN)
- Southwest Hospital (CN)
- First Hospital of China Medical University (CN)
- Chinese People's Liberation Army (CN)
- Ocean University of China (CN)
- China Medical University (CN)
Publication Details
- Journal
- MedComm
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1002/mco2.762
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Army Medical University
- National Key Research and Development Program of China